Negros Occidental LGUs Highlight Sustainable Practices In Panaad Fest Booths

Ipinapakita ng Panaad sa Negros Festival ang dedikasyon ng mga LGU sa mga sustainable na praktis para sa kalikasan.

Criteria Set For BHWs Serving As Health Education Officers

Ang Iloilo City ay naglatag ng mga pamantayan upang tiyakin ang kalidad ng mga BHW bilang Health Education Officers.

DBM Oks 1.2K Additional Posts For Philippine General Hospital

Ang DBM ay nag-apruba ng 1,224 bagong posisyon sa PGH upang suportahan ang kanilang lumalawak na pangangailangan sa tauhan.

DSWD Tightens AKAP Rules, Limits Aid To Below-Minimum Wage Earners

Dagdag-pahayag mula sa DSWD, ang financial aid ay limitado na sa mga hindi umaabot sa minimum wage.

FDA Approves New Alzheimer’s Drug That Appears To Slow Illness

The United States Food and Drug Administration confirmed that a newly discovered drug can now slow down the growth of Alzheimer's disease.
By The Visayas Journal

FDA Approves New Alzheimer’s Drug That Appears To Slow Illness

57
57

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

The US Food and Drug Administration (FDA) on Friday approved a new drug that appears to slow the progression of Alzheimer’s disease.

The FDA said Leqembi — known chemically as lecanemab — will be prescribed to patients with mild or early stages of the brain-deteriorating disease.

The drug is the first of its kind to convincingly show researchers that it can slow the decline in memory and thinking.

However, experts said the delay in cognitive deterioration caused by the drug will likely amount to just several months, which in some cases is a very long time for families with loved ones who suffer from Alzheimer’s.

“This drug is not a cure. It doesn’t stop people from getting worse, but it does measurably slow the progression of the disease,” said Joy Snider, a neurologist at Washington University in St. Louis, in an interview with NBC. “That might mean someone could have an extra six months to a year of being able to drive.”

Medical experts said the drug comes with risks and downsides, including possible side effects like brain swelling and the need for twice-a-month infusions.

Leqembi is manufactured by Japan’s Eisai and its US partner Biogen. The company said the drug will cost about $26,500 for a typical year’s worth of treatment, citing that the high price tag reflects the drug’s benefits, including improved quality of life and reduced burdens for caregivers.

The challenge in getting the drug to patients is the next hurdle, as it may be several months before Leqembi can be distributed and insurers must now decide whether and how to cover the drug’s high cost.

The FDA’s approval was based on one mid-stage study in 800 people with early signs of Alzheimer’s who were still able to live independently or with minimal assistance.

Eisai also published the results of a larger 1,800-patient study that the FDA will review to confirm the drug’s benefits.

According to health experts, nearly six million Americans suffer from Alzheimer’s with millions more suffering from the disease worldwide.

Alzheimer’s disease gradually attacks areas of the brain needed for memory, reasoning, communication and daily tasks. (PNA)